• Title of article

    IV Ciprofloxacin-Induced Phlebitis: Investigating the Impact of Pharmaceutical and Process-Related Factors on Patient Safety

  • Author/Authors

    Hosseini ، Sareh Department of Pharmacovigilance - Ronak Pharmaceutical Co , Mohammadi ، Alireza Ronak Pharmaceutical Co. , Fattahi ، Alborz Ronak Pharmaceutical Co. , Hashemi ، Shiva Ronak Pharmaceutical Co. , Khajeamiri ، Yasaman Ronak Pharmaceutical Co.

  • From page
    195
  • To page
    197
  • Abstract
    Transient phlebitis is a rare but notable adverse reaction that can occur following intravenous administration of various medications, including ciprofloxacin, an antibiotic recognized for its broad-spectrum activity. This case report discusses a 48-year-old male patient with poorly controlled type 2 diabetes who developed phlebitis after receiving undiluted ciprofloxacin via a peripheral intravenous line. Symptoms emerged within 24 hours, characterized by swelling and redness at the injection site, prompting the discontinuation of the medication. Analysis revealed that improper dilution and rapid infusion rate were major factors contributing to the development of phlebitis. This underscores the importance of adhering to guidelines provided in product information leaflets for intravenous drug preparation and administration. The case emphasizes the critical need for healthcare professionals to follow recommended protocols to reduce the risk of infusion-related complications, especially in patients with underlying comorbidities.
  • Keywords
    Thrombophlebitis , Pharmacovigilance , Adverse drug reaction
  • Journal title
    Journal of Pharmaceutical Care
  • Journal title
    Journal of Pharmaceutical Care
  • Record number

    2778509